Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000392727

Medchemexpress LLC JMJD1C-IN-1 | 861224-48-8 | 100.0% | 317.36 | 100 MG
SDP

Catalog No. 5000392727
Encompass_Preferred

This product is an orally active and selective inhibitor that targets JMJD1C, preventing its binding to H3K9me2 peptide substrate. It improves antitumor immunity by disrupting intratumoral regulatory T cell fitness, promoting H3K9me2 accumulation to downregulate PD1 expression, and enhancing STAT3 activation. It has shown dose-dependent antitumor efficacy in multiple mouse tumor models and is valuable for tumor immunotherapy research.

  • Orally active and selective inhibition of target.
  • Inhibits target binding to H3K9me2 peptide substrate.
  • Disrupts intratumoral regulatory T cell fitness for improved antitumor immunity.
  • Promotes H3K9me2 accumulation, downregulating PD1 expression.
  • Enhances STAT3 activation by reducing demethylation.
  • Demonstrates dose-dependent antitumor efficacy across various mouse tumor models.
  • Exhibited no significant toxicity in animal models.

Catalog No. 50-003-92727 Supplier Medchemexpress LLC Supplier No. HY162275100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

This product is an orally active and selective inhibitor that targets JMJD1C, preventing its binding to H3K9me2 peptide substrate. It improves antitumor immunity by disrupting intratumoral regulatory T cell fitness, promoting H3K9me2 accumulation to downregulate PD1 expression, and enhancing STAT3 activation. It has shown dose-dependent antitumor efficacy in multiple mouse tumor models and is valuable for tumor immunotherapy research.

  • Orally active and selective inhibition of target.
  • Inhibits target binding to H3K9me2 peptide substrate.
  • Disrupts intratumoral regulatory T cell fitness for improved antitumor immunity.
  • Promotes H3K9me2 accumulation, downregulating PD1 expression.
  • Enhances STAT3 activation by reducing demethylation.
  • Demonstrates dose-dependent antitumor efficacy across various mouse tumor models.
  • Exhibited no significant toxicity in animal models.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.